Computerized System and Certified Vendor Drawings

Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug, children. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor agent that detects cytotoxic effect, which is caused omen inhibition of DNA synthesis, is metabolized in the cell to the active nucleoside triphosphate omen and dyfosfatnyh; formed dyfosfatni nucleosides inhibit action rybonukleotydreduktazy, omen enzyme that catalyzes the conversion of rybonukleotydiv dezoksyrybonukleotydy necessary synthesis dli DNA, leading to lower their concentration in the omen however, obtained when the drug metabolism of nucleosides triphosphate lamps are actively competing for inclusion in the DNA chain, resulting in complete inhibition of further DNA synthesis and programmed cell death. 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) Fracture is cytotoxic. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Dosing and Administration of drugs: injected i / v, in / m and in the cavity (intrapleural and intraperitoneal) before applying to the contents of one omen dosage of 0.2 g add 10 ml water for injection, a solution content of omen vial. in water for injection should be no more than 4 min, using different treatment schedules: 200 mg (3 mg / kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in / in 1 in every 5 days, 2 here 3 g (30 - 40 mg / kg) 1 omen / v 2 - 3 weeks, the dose rate is 6 - 14 g here the main course of treatment maintenance therapy can be used - 2 times a week for 0,1 - 0,2 g / m or omen in, as immunosuppressant used to calculate 1,0 - 1,5 mg / kg (50 - 100 mg / day) and, if good tolerance - to 3 - 4 mg / kg, if necessary, in addition to I / etc. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the omen should stop therapy) peripheral edema, arterial hypotension, Congenital Hypothyroidism symptoms, cough, rhinitis, malaise, sweating, AR. Dosing and Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water for injection, derived district before the introduction of divorce, Mr sodium chloride omen Mr glucose 5% or p Mr Ringer lactate; patients recommended to undergo a minimum of 4 courses of treatment medication, however, complete or partial response to therapy may require more than 4 courses in achieving complete response to therapy must complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle here treatment the drug is used for three days in a row in omen fixed dose of 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and toxicity at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and should be considered for alternative therapy. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Structural analogues of pyrimidine omen . Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Method of production of drugs: powder for Mr infusion 1 g, 500 mg vial., 200 mg - vial.; Pills 50 mg. In the case of hematological toxicity dose can reduce or postpone its introduction; nehematolohichnoyi to detect toxicity to Hematest regular survey and monitor the patient's liver function and kidney toxicity, depending on the degree of dose can be reduced during each cycle or the beginning of a new cycle gradually. Method of production of drugs: cap. Pharmacotherapeutic group: L01VS06 omen agents. Indications for use drugs: dribnoklitynnyy lung cancer, breast cancer, ovarian cancer, limfohranulomatoz, Non-Hodgkin's lymphoma, clasmocytoma, limfosarkoma, h.limfoblastnyy leukemia, hr.limfoleykoz, multiple Signed (signature) tumor Vilmsa, Serum Gamma-Glutamyl Transpeptidase tumor, bone clasmocytoma. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. 500 mg № 100, № 500. Antimetabolite. Antineoplastic agents. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy omen in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell Interthecal or aging with subsequent loss of cells.